about
HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approachLiquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discoveryCleavage of the amino terminus of the prion protein by reactive oxygen species.[Clinical proteomics: towards early detection of cancers].[Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].Clinical proteomics and mass spectrometry profiling for cancer detection.Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells.Proteomic analysis of RCL2 paraffin-embedded tissues.Comprehensive proteomic analysis of the human milk proteome: contribution of protein fractionation.[Comparison of proteomic strategies to identify antibodies resulting from the humoral immune response to cancer].Highly sensitive detection of melanoma based on serum proteomic profiling.Trafficking of the cellular isoform of the prion protein.Pemphigus vulgaris antigen mRNA quantification for the staging of sentinel lymph nodes in head and neck cancer.Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures.Use of autoantibodies to detect the onset of breast cancerComparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencingPrion infection impairs the cellular response to oxidative stressProteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotic fluids.D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile.Identifying autoantibody signatures in cancer: a promising challenge.FKBP family proteins as promising new biomarkers for cancer.Proteomic approaches to identify biomarkers predictive of radiotherapy outcomes.Late side-effects after curative intent radiotherapy: Identification of hypersensitive patients for personalized strategy.Proteomic analysis of differently archived breast cancer tissues.KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissuesAn integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ.Scrapie-like prion protein is translocated to the nuclei of infected cells independently of proteasome inhibition and interacts with chromatin.Alpha- and beta- cleavages of the amino-terminus of the cellular prion protein.A strong inhibitory element down-regulates SRE-stimulated transcription of the A3 cytoplasmic actin gene of Bombyx mori.Elevated concentrations of milk β2-microglobulin are associated with increased risk of breastfeeding transmission of HIV-1 (Vertical Transmission Study).[Cell culture models of transmissible spongiform encephalopathies].PrP-dependent cell adhesion in N2a neuroblastoma cells.Stimulation of PrP(C) retrograde transport toward the endoplasmic reticulum increases accumulation of PrP(Sc) in prion-infected cells.Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival.[Scrapie, proteasome and endoplasmic reticulum].Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.Effect of amphotericin B on wild-type and mutated prion proteins in cultured cells: putative mechanism of action in transmissible spongiform encephalopathies.Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: application to the sensitive and specific detection of tumor markers from breast cancer sera.
P50
Q28481613-315CE4D9-8802-4C62-AD14-228DE6CDF91FQ30478449-6C62610B-B2D9-4F25-9DB5-59F3116C18D6Q31520300-7B5775E7-9705-4317-879C-BEC9FAD46162Q33222093-6983BCB4-D10F-4A23-8406-E328E34FC8C1Q33224534-C7AC08A6-CC17-4519-A2F1-30FD2D7E5008Q33246668-71538CD7-382E-4359-8215-B25F1565512EQ33356491-07180497-1E73-4C9E-A4B1-6D6ADAB7C11BQ33358575-81F5889C-E7C1-412C-A010-B8562981B6E3Q33384726-1FA22F8B-91AB-41D8-8A47-84B8914A6E9AQ33385579-0C77D9D6-BD9F-498A-A70F-E776C24367C6Q33396595-989FE44D-029A-494A-9F52-7000040C2482Q33418426-22B35B51-C3FF-438C-B28E-34312B69FDF3Q33604103-C7E2CEEF-44CF-46DA-BED4-8E78665BA599Q33620021-0A756A7A-DCF9-4F5A-84CE-2E0CA4CD7719Q33801179-CC46FEC6-E4EE-42DE-BA2A-AD659445B615Q34037876-43C7CA08-6B06-415B-8F6B-1BF5C3670EB9Q34469532-E9D19860-1F99-473F-A7CB-31D0286A14C2Q35581657-2BC5429A-5920-4E4F-BB82-467E55096707Q36470088-958AB249-C316-43DE-9350-AAACB4222A9CQ36528525-D8BCE4BF-8E26-4D77-9683-F3A38CCC8A67Q37579900-D9F9E49F-62FB-4292-B47B-7DFC91181CA4Q37868159-C905CB52-6CB4-4B33-ACA2-DAC3BBB56B43Q38081954-B8CF84BC-34A8-4CEA-B177-EFA1C6D5AA80Q38286519-44942917-F724-405D-8DBC-AD95D0C69686Q38404871-75B7791A-EC6C-414E-B211-AFF3684EDD52Q38409695-FAE7A2F2-AC71-4AB4-A089-3059E33FFF6DQ38771754-5EC8EC90-269D-4019-84D2-13720A1EFCF2Q39953442-82982BEC-D451-490B-AE9A-66BEB6AF719BQ40558969-BF8252D6-9722-4696-8E24-03547C9C30B7Q40572421-4681BD13-D086-49DC-B25F-B817469246CFQ42062863-27F6E731-95D5-4C29-B6C4-7C6A8AD4E8DEQ42243498-28CC1B5B-A74E-44DF-8735-55C877E4A02CQ43894109-DC9C5B14-9409-4294-B938-D505C6CB5FE6Q43953788-2079506F-2C55-4A31-BEEB-5F97D27BE738Q44090721-83D40CF2-250B-480B-B239-FD7FB2C2D738Q44391055-BE0F5B6B-4FC0-4F46-B423-BD1D31E4B628Q44639578-5B846DE8-400D-4453-99DB-A214BEB89841Q45936703-4D9D147E-8AED-4ABA-A3FB-B422D773BB5FQ46798865-56434DA3-05CB-408F-BE19-D68643D92577Q46838881-F3471118-A12F-49B5-A8F6-AAB1EA2C55E6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alain Mangé
@ast
Alain Mangé
@en
Alain Mangé
@es
Alain Mangé
@nl
type
label
Alain Mangé
@ast
Alain Mangé
@en
Alain Mangé
@es
Alain Mangé
@nl
prefLabel
Alain Mangé
@ast
Alain Mangé
@en
Alain Mangé
@es
Alain Mangé
@nl
P106
P21
P31
P496
0000-0002-1566-9407